



550 E. Swedesford Road
Suite 370
Wayne, PA 19087
Tel: (484) 582-6100

Notice of Change in Distribution Model for TYMLOS®

March 2, 2020

This notice provides information for eligible 340B covered entities regarding the distribution model change and how to acquire TYMLOS® (abaloparatide) injection (NDC 70539-0001-02). Radius Health, Inc. (“Radius”) recently modified its distribution model. This modification does not restrict the ability of eligible 340B entities to obtain TYMLOS® at the 340B price.

Moving forward, 340B eligible entities will only be able to purchase TYMLOS® through select specialty distributors. Contact information for these specialty distributors can be found at <https://radiuspharm.com/wp-content/uploads/tymlos/radius-health-authorized-distributors-of-record.pdf>.

Radius is fully committed to compliance with the 340B statute. If you have any questions about this change in the distribution model for TYMLOS® or experience any difficulty in obtaining TYMLOS® for your patients, please contact Radius at trade@radiuspharm.com.